MN-TRU-VUE
Opened Oct. 22, 2021, the new MUNCH Museum in Oslo, Norway, displays the works of Edvard Munch (1863-1944). While Munch produced a large, complex body of work, he is most well-known for “The Scream.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116006464/en/
For the new museum, WERNER MURRER RAHMEN and HALBE Rahmen of Germany created over 500 frames to strict conservation requirements, keeping with the aesthetic of Munch’s style. Tru Vue ® Optium Museum Acrylic ® protects these world-famous artworks with an intimate viewing experience.
To watch a documentary film and learn more about MUNCH Museum’s reframing project, visit https://tru-vue.com/2021/11/new-frames-fitted-with-optium-museum-acrylic-at-munchmuseet/.
MUNCH Museum’s dual-frame system has a visible exterior and a concealed interior.
WERNER MURRER RAHMEN hand-made the outer, decorative wood framing, modeled after extensive historical research on original Munch frames. Munch used simple, wood frames and frequently left his artwork outside to directly interact with nature, resulting in a unique patina.
HALBE Rahmen engineered the vault-like, inner framing with Optium Museum Acrylic and a slim aluminum profile, which is essentially indiscernible beneath the wooden overlay. A magnetic closure allows the artwork to be front-loaded to reduce handling.
“It’s a beautiful system,” praised Barbara De Haan, MUNCH Museum’s relocation project leader. “Frames are extremely important.” Observing one of Munch’s pieces with its new frame and Optium Museum Acrylic, she commented, “It’s perfect. You see how the work comes alive. It speaks to you.”
“It was important that visitors to the new MUNCH Museum could get as close as possible to the artist’s work, to really feel and experience it; all while keeping the works protected,” said Tru Vue director of fine art and museums, Dr. Jennifer Booth. “We don’t want them to notice our product. We want them to get lost in the artwork, to see the texture of the paint, to be carried away in the emotion of the piece, rather than having that barrier.”
“With Optium Museum Acrylic, it is like you are close to the canvas with no glass in front. Glazing is necessary, but it is perfect if you don’t see it,” noted Werner Murrer.
David Halbe added, “The glazing that is in between the artwork and the visitor is very important. It should protect the painting without disturbing the view.”
Johan Øvergård, art technical manager at MUNCH, said, “The advantage of using Tru Vue Optium Museum Acrylic compared to laminated glass is the reduced weight, which eases handling, transporting and installing the artworks.” The system also allows for Munch’s artworks to be loaned internationally.
Serving museums and custom framers worldwide, Tru Vue, Inc. manufacturers UV-protective, anti-reflective, and high-performance glass and acrylic in the U.S.
“The coating process is a combination of a lot of science and a touch of art from our technical teams,” said Nate Soukup, Tru Vue vice president of operations. “We’ve worked tirelessly to perfect the production of Optium® over the last 20 years. We’ve developed the ability to produce acrylic in high volume, large sizes and with extremely tight quality specifications that our customers, like the MUNCH Museum, require.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116006464/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
